Mylan's Nebivolol Is "Approvable" At FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The beta blocker's user fee date had been extended by three months following submission of additional analysis. Mylan expects the anti-hypertensive to be the cornerstone of its brand division.
You may also be interested in...
Mylan Finds Its Way Out Of The Woods: Forest Signs Nebivolol Licensing Agreement
Forest will assume development, sales and marketing rights for Mylan's beta blocker.
Mylan Finds Its Way Out Of The Woods: Forest Signs Nebivolol Licensing Agreement
Forest will assume development, sales and marketing rights for Mylan's beta blocker.
Mylan Would Launch Nebivolol For Hypertension If Heart Failure Indication Is Delayed
Timeline could hinge on FDA’s acceptance of heart failure data from the SENIORS trial; nebivolol is currently “approvable” for hypertension.